Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162045 · ClinicalTrials.gov registry record · Phase 1
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
A Phase 1 study, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT00162045 is a Phase 1 study that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 79 participants.
The verdict
NCT00162045, a Phase 1 study, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
Interventions
- DRUG Technetium Tc99m Sestamibi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162045
The ClinicalTrials.gov registry entry for NCT00162045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technetium Tc99m Sestamibi is the first listed.
NCT00162045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162045 about?
NCT00162045 is a clinical study titled "A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects". The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
What is the current status of trial NCT00162045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2005-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00162045?
The interventions under investigation include: Technetium Tc99m Sestamibi (DRUG).
Who is sponsoring clinical trial NCT00162045?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.